Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB announced that a majority of its board and management have acquired shares worth over SEK 1 million, demonstrating strong internal confidence in the company’s future. This move follows the company’s recent strategic focus on early intervention in autoimmune and inflammatory diseases, particularly rheumatoid arthritis, and host-directed treatment in viral infections, positioning SynAct for successful execution of its plans.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company that focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
Average Trading Volume: 229,498
Current Market Cap: SEK866.5M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.